Kwangdong Pharmaceutical

KSC:009290 · KR7009290008

PharmaceuticalsSmall

360

Medium confidence — indicative

Value61

Profit price41

EV / EBIT65

Price / Owner Earnings16

Cash yield40

Owner Earnings Yield78

Dividend Yield1

Sales & asset price91

Price/Sales97

EV / Gross Profit86

Price/Book91

Quality61

Returns on capital71

Return on Capital74

Cash Return on Capital72

Return on Equity68

Profit margins59

EBIT Margin59

Gross Profitability59

Cash backing55

Cash Conversion89

Accruals14

Owner Earnings Margin63

Growth60

Sales growth62

Profit growth69

Profit Growth53

Long-Term EPS Growth85

Reinvestment4

Price momentum79

Safety36

Debt load36

Debt serviceability56

Refinancing92

Debt Payback20

Liquidity37

Sentiment63

Analyst ratings—

Expectations trend—

Market mood34

Value Creation12/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Kwangdong Pharmaceutical clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

TypePublic Company

ExchangeKOSE

Employees29

Websiteekdp.com

ISINKR7009290008

Last UpdateApr 2, 2026

Indices

KOSPI (South Korea)

Themes

OphthalmologyPain ManagementNutraceuticalNeurologyInflammationObesityCentral Nervous SystemBiotechnologyHealth CarePharmaceutical

Description

Analysis

Middle-of-the-road

Kwang Dong Pharmaceutical Co., Ltd. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

The price is attractive. You pay 11.2× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone.

The trajectory is moderate and the balance sheet is stretched. The company scores 12/20 on our value-creation score: creating some value. Analysts lean positive.

What to watch: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

20232026

All-time high

Jan 2023

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

100

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Kwangdong Pharmaceutical with its peers

Hana Pharm

KSC:293480

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Samsung Pharm

KSC:001360

—

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

KSC:096760

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Dong-A Socio

KSC:000640

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Bukwang Pharmaceutical

KSC:003000

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Dongwha Pharm

KSC:000020

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →